$ASND News

Ascendis Pharma (ASND) Reimbursement Win Puts Its Fair Value Narrative Back In Focus

Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312

Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273

Ascendis Pharma (NASDAQ:ASND) Passes Minervini Trend Template and High Growth Momentum Screen

Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target

B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304

Jefferies Maintains Buy on Ascendis Pharma, Lowers Price Target to $330

Stifel Maintains Buy on Ascendis Pharma, Lowers Price Target to $326

HC Wainwright & Co. Maintains Buy on Ascendis Pharma, Lowers Price Target to $344

Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes

Ascendis, Biomarin Enter Binding Global Settlement And License Agreement Resolving All Litigation, Granting Ascendis Worldwide Rights To Develop, Commercialize Navepegritide Products, With Royalty Payments On YUVIWEL Sales Through 2030

HC Wainwright & Co. Reiterates Buy on Ascendis Pharma, Maintains $345 Price Target

HC Wainwright & Co. Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $345

If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine

Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript

Is Ascendis Pharma (ASND) Priced Too Richly After Recent Progress?

Ascendis Pharma (ASND) Reports Earnings And Trial Updates, Is It Fully Priced?

BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319